Lupin Receives Approval From U.S. FDA For Pirfenidone Tablets

Lupin Receives Approval From U.S. FDA For Pirfenidone Tablets

This product will be manufactured at Lupin’s Pithampur facility in India.

FPJ Web DeskUpdated: Friday, August 25, 2023, 01:22 PM IST
article-image
Lupin Receives Approval From U.S. FDA For Pirfenidone Tablets | Image: Lupin (Representative)

Global pharma major Lupin Limited on Friday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pirfenidone Tablets, 267 mg and 801 mg, to market a generic equivalent of Esbriet Tablets, 267 mg and 801 mg of Hoffmann La Roche Inc, through an exchange filing. This product will be manufactured at Lupin’s Pithampur facility in India.

Pirfenidone Tablets (RLD Esbriet) had estimated annual sales of USD 218 million in the U.S. (IQVIA MAT June 2023).

Lupin earlier this month announced the acquisition of diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), including the trademark rights associated with these brands.

Lupin shares

The shares of Lupin Limited on Friday afternoon at 1:20 pm IST were trading at Rs 1,079.70, down by 0.90 per cent.

RECENT STORIES

Bangalore Peripheral Ring Road - The Upcoming Economic Corridor: Priyatham Kumar, Founder Of...

Bangalore Peripheral Ring Road - The Upcoming Economic Corridor: Priyatham Kumar, Founder Of...

Key Characteristics Of Business Loans In 2024

Key Characteristics Of Business Loans In 2024

Unlocking Financial Freedom With Steadyincome.in: Your Ultimate Fixed Income Investment Platform

Unlocking Financial Freedom With Steadyincome.in: Your Ultimate Fixed Income Investment Platform

How To Prepare Yourself For Upcoming Tax Season India?

How To Prepare Yourself For Upcoming Tax Season India?

Adventure Powerhouse: Benelli TRK 552X Unveiled

Adventure Powerhouse: Benelli TRK 552X Unveiled